Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 nm » 5 mm (Expand Search), 5 cm (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 nm » 5 mm (Expand Search), 5 cm (Expand Search)
-
181
Increases in 1,5-anhydrosorbitol and decreases in ascorbic acid following RYGB.
Published 2013“…B) For ascorbic acid, the ANOVA model did not detect group-specific changes over time (no group:time interaction), but indicated significant decreases from T0 to T6 in both groups. Overall, 1,5-anhydrosorbitol and ascorbic acid were significantly different at each time point between OB and OB/D subgroups (p<0.01, see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0007905#pone-0007905-t002" target="_blank"><b>TABLE 2</b></a>).…”
-
182
-
183
-
184
-
185
Cell surface CHT levels are unchanged by altered PI3-Kinase signaling in non-depolarized cells.
Published 2015Subjects: -
186
-
187
Genetic correlations in viral load between single and coinfections of CrPV and DCV.
Published 2023Subjects: -
188
Interspecific correlations in viral load between single and coinfections of CrPV and DCV.
Published 2023Subjects: -
189
-
190
-
191
-
192
-
193
-
194
-
195
Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5‑ASA–PABA–MAC and 5‑ASA–PABA–Diamine for the T...
Published 2022“…Specifically, compound <b>20g</b> displayed a 3.67-fold decrease of plasma AUC<sub>(tofacitinib, 0–∞)</sub> and a 9.61-fold increase of colonic AUC<sub>(tofacitinib, 0–12h)</sub>, compared with tofacitinib at a molar equivalent oral dose. …”
-
196
-
197
-
198
-
199
-
200